Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (NCT07284433)
A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.
Who can join: Review the eligibility criteria below.
Location: University of Chicago — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Chicago — Chicago, Illinois
- Northwestern University — Evanston, Illinois
- Brown University Health — Providence, Rhode Island
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Universitätsklinikum Ulm — Ulm, Baden-Wurttemberg
- Universitätsklinikum Erlangen — Erlangen, Bavaria
- Klinikum der Universität München — Munich, Bavaria
- Universitätsklinikum Marburg — Marburg, Hesse
- Uniklinikum Erlangen — Essen, North Rhine-Westphalia
- Universitätsklinikum Dresden — Dresden, Saxony
- Charité Universitätsmedizin Berlin — Berlin,
- Universitätsklinikum Hamburg-Eppendorf — Hamburg,
📞 Contact the Study Coordinator
Phone: 0493514466450
Email: avc-203-01@avencell.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Lymphoma Diffuse Large B-cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.